Your Health, We Care
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
from FDA,2023.09
Momelotinib is indicated for the treatment of intermediate or high-risk myelofib···【more】
Release date：2026-01-05Recommended：14
Lucius Version of Momelotinib: Dosage and Administration, Indications, Precautio···【more】
Release date：2025-12-16Recommended：61
